Title:
MUSCLE STEM CELL OR MYOBLAST, METHOD FOR SCREENING SUBSTANCES THAT PARTICIPATE IN METABOLIC CONVERSION USING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SUBSTANCE OBTAINED FROM SAID SCREENING METHOD
Document Type and Number:
WIPO Patent Application WO/2015/060430
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a method for screening substances that participate in metabolic conversion and a kit for screening substances that participate in metabolic conversion. Said problem can be solved with muscle stem cells or myoblasts comprising at least one myosin heavy chain fusion gene selected from a group consisting of: a myosin heavy chain I fusion gene in which a myosin heavy chain I gene is bonded to a fluorescent or luminescent protein gene; a myosin heavy chain IIa fusion gene in which a myosin heavy chain IIa gene is bonded to a fluorescent or luminescent protein gene; a myosin heavy chain IId/x fusion gene in which a myosin heavy chain IId/x gene is bonded to a fluorescent or luminescent protein gene; and a myosin heavy chain IIb fusion gene in which a myosin heavy chain IIb gene is bonded to a fluorescent or luminescent protein gene.
More Like This:
Inventors:
SHIGEMOTO KAZUHIRO (JP)
Application Number:
PCT/JP2014/078366
Publication Date:
April 30, 2015
Filing Date:
October 24, 2014
Export Citation:
Assignee:
TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INST OF GERONTOLOGY (JP)
International Classes:
C12N5/10; A61K31/436; A61K38/22; A61P1/04; A61P3/04; A61P3/10; A61P9/04; A61P9/10; A61P11/00; A61P17/02; A61P21/00; A61P21/02; A61P21/04; A61P25/00; A61P41/00; A61P43/00; C12Q1/02; G01N33/15; C12N15/09
Domestic Patent References:
| WO2013116691A1 | 2013-08-08 |
Other References:
EGHTESAD S. ET AL.: "Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle", MOL.MED., vol. 17, no. 9-10, September 2011 (2011-09-01), pages 917 - 24, XP055289856
MINIACI M.C. ET AL.: "CL316,243, a selective beta3-adrenoceptor agonist, activates protein translation through mTOR/p70S6K signaling pathway in rat skeletal muscle cells", PFLUGERS ARCH., vol. 465, no. 4, 4 April 2013 (2013-04-04), pages 509 - 16, XP055289863
PARK IH. ET AL.: "Mammalian target of rapamycin (mTOR) signaling is required for a late-stage fusion process during skeletal myotube maturation", J.BIOL.CHEM., vol. 280, no. 36, 9 September 2005 (2005-09-09), pages 32009 - 17, XP055289869
WANG Q. ET AL.: "Mutations in the motor domain modulate myosin activity and myofibril organization", J. CELL .SCI., vol. 116, no. 20, 15 October 2003 (2003-10-15), pages 4227 - 4238, XP055289875
NORIYUKI OUCHI: "Kokkakukin Yurai Bunpitsu Inshi Myokine to Shikkan", MODERN PHYSICIAN, vol. 31, no. 11, November 2011 (2011-11-01), pages 1356 - 1358, XP008181529
LYNCH G.S.: "Novel therapies for sarcopenia: ameliorating age-related changes in skeletal muscle", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 12, no. 1, January 2002 (2002-01-01), pages 11 - 27, XP002426287
MUSCLE & NERVE, vol. 47, 2013, pages 691 - 701
INTERNATIONAL JOURNAL OF CARDIOLOGY, vol. 168, 2013, pages 2014 - 21
PROGRESS IN BRAIN RESEARCH, vol. 201, 2012, pages 333 - 59
PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, 2006, pages 16864 - 9
"Visualization of composition shift of muscle fibers by training using a biological imaging, -Construction of novel model animal for reseach", MIZUNO SPORTS PROMOTION FOUNDATION, AID FOR SCIENTIFIC, ACADEMIC, OR MADICAL STUDY ON SPORTS, 2010
TERRETT, N. K. ET AL., TETRAHEDRON, vol. 51, 1995, pages 8135 - 8137
FELICI, F. ET AL., J. MOL. BIOL., vol. 222, 1991, pages 301 - 310
SETH A. WADER ET AL., JOURNAL OF CLINICAL INVESTIGATION, vol. 121, 2011, pages 1231 - 41
See also references of EP 3061810A4
MINIACI M.C. ET AL.: "CL316,243, a selective beta3-adrenoceptor agonist, activates protein translation through mTOR/p70S6K signaling pathway in rat skeletal muscle cells", PFLUGERS ARCH., vol. 465, no. 4, 4 April 2013 (2013-04-04), pages 509 - 16, XP055289863
PARK IH. ET AL.: "Mammalian target of rapamycin (mTOR) signaling is required for a late-stage fusion process during skeletal myotube maturation", J.BIOL.CHEM., vol. 280, no. 36, 9 September 2005 (2005-09-09), pages 32009 - 17, XP055289869
WANG Q. ET AL.: "Mutations in the motor domain modulate myosin activity and myofibril organization", J. CELL .SCI., vol. 116, no. 20, 15 October 2003 (2003-10-15), pages 4227 - 4238, XP055289875
NORIYUKI OUCHI: "Kokkakukin Yurai Bunpitsu Inshi Myokine to Shikkan", MODERN PHYSICIAN, vol. 31, no. 11, November 2011 (2011-11-01), pages 1356 - 1358, XP008181529
LYNCH G.S.: "Novel therapies for sarcopenia: ameliorating age-related changes in skeletal muscle", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 12, no. 1, January 2002 (2002-01-01), pages 11 - 27, XP002426287
MUSCLE & NERVE, vol. 47, 2013, pages 691 - 701
INTERNATIONAL JOURNAL OF CARDIOLOGY, vol. 168, 2013, pages 2014 - 21
PROGRESS IN BRAIN RESEARCH, vol. 201, 2012, pages 333 - 59
PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, 2006, pages 16864 - 9
"Visualization of composition shift of muscle fibers by training using a biological imaging, -Construction of novel model animal for reseach", MIZUNO SPORTS PROMOTION FOUNDATION, AID FOR SCIENTIFIC, ACADEMIC, OR MADICAL STUDY ON SPORTS, 2010
TERRETT, N. K. ET AL., TETRAHEDRON, vol. 51, 1995, pages 8135 - 8137
FELICI, F. ET AL., J. MOL. BIOL., vol. 222, 1991, pages 301 - 310
SETH A. WADER ET AL., JOURNAL OF CLINICAL INVESTIGATION, vol. 121, 2011, pages 1231 - 41
See also references of EP 3061810A4
Attorney, Agent or Firm:
MORITA Kenichi et al. (JP)
Ken-ichi Morita (JP)
Ken-ichi Morita (JP)
Download PDF: